​Principal Investigator: Dr. Koba Privat Agniwo

Disease: Schistosomiasis

Research Description: Schistosomiasis is the second most widespread parasitic infection in sub-Saharan Africa, contributing to chronic illness, malnutrition, cognitive development impairment and more in children. While the drug praziquantel is approved to treat schistosomiasis, it only targets the adult parasitic worms and not the young worms, allowing these worms to mature and causing reinfections and disease persistence. Artesunate-pyronaridine, approved for malaria, was shown via artificial intelligence (AI) models and preclinical experiments to inhibit young worms. This Phase IIA, randomized, controlled trial is combining praziquantel with artesunate-pyronaridine to provide coverage against schistosomiasis throughout the worms’ life cycle and could potentially provide a safe, effective and accessible combination therapy to improve the health and quality of life for children in Mali.

Funding Partners: Biohub and Lyda Hill Philanthropies

Initial CWR Funding Role: Primary